Cardio-IT

Quality in CARDIOlogy
Medical Informational Technology
Working group

Erythropoietin is a marker of chronic kidney disease at the pre-clinical stage

Journal title: 
Year: 
Authors: 
Borodulin V.B., Bychkov E.N., Protopopov A.A., Rebrov A.P., Shevchenko O.V., Nesterenko O.V., Kiselev A.R., Bobyleva E.V.
Article type: 
Full text in: 
Abstract: 
In this study, we investigated the use of erythropoietin as an early marker of chronic kidney disease (CKD). Methods: 72 patients with CKD (42 % male) aged 51,7 ± 13,4 years and 10 healthy subjects (50 % male) aged 49,6 ± 11,2 years were included in our study. All patients have full clinical diagnostics of CKD and blood level of erythropoietin. Results: It was shown that blood level of erythropoietin in patients with 1, 2 and 3rd stages of CKD was significantly (p < 0.05) higher than in healthy subjects. The patients with 4 stage of CKD have erythropoietin level comparable to healthy subjects. Conclusion: Increased erythropoietin levels in blood associated with the progression of CKD, which can be used in the early diagnosis of CKD.
Cite as: 
Borodulin VB, Bychkov EN, Protopopov AA, Rebrov AP, Shevchenko OV, Nesterenko OV, Kiselev AR, Bobyleva EV. Erythropoietin is a marker of chronic kidney disease at the pre-clinical stage. Fundamental Research 2013; (11-1): 22-26.

Full text: PDF, HTML